Pharmacological treatment of adhd and the short and long term effects on sleep

Current Pharmaceutical Design

Volumn 17, Issue 15, 2011, Pages 1450-1458

  Huang, Yu Shu ^a,b   Tsai, Ming Horng ^a,b,c   Guilleminault, Christian ^d  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Attention deficit hyperactivity disorder; Comorbidity; Medication; Sleep; Stimulants

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DOPAMINE; GUANFACINE; IMIPRAMINE; LISDEXAMFETAMINE; METHYLPHENIDATE; NORADRENALIN; NORTRIPTYLINE; PEMOLINE; PLACEBO; PROPRANOLOL; PSYCHOSTIMULANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ACTIMETRY; ANOREXIA; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DOPAMINE RELEASE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INSOMNIA; MORNING DOSAGE; NAUSEA; NORADRENALIN RELEASE; PARASYMPATHETIC FUNCTION; PERIODIC LIMB MOVEMENT DISORDER; POLYSOMNOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REM SLEEP; REM SLEEP ONSET LATENCY; RESTLESS LEGS SYNDROME; REVIEW; SEDATION; SIDE EFFECT; SLEEP; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SLEEP ONSET LATENCY; SLEEP PARAMETERS; SOMNOLENCE; SYMPATHETIC FUNCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WAKEFULNESS;

ACTIGRAPHY; ADOLESCENT; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DOPAMINE; HUMANS; METHYLPHENIDATE; NOREPINEPHRINE; POLYSOMNOGRAPHY; QUALITY OF LIFE; SLEEP DISORDERS; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84863022949     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796197179     Document Type: Review

References (119)

1. Brown RT, Freeman WS, Perrin JM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001; 107: E43.
2. Arnsten AF. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009; 23: Suppl 1: 33-41.
3. Arnsten AF. The emerging neurobiology of attention-deficit hyperactivity disorder: the key role of the prefrontal association cortex. J Pediatr 2009; 145: 1-S43.
4. Devilbiss DM, Berridge CW. Cognition-enhancing doses of methylphenidate preferentially increase prefrontal cortex neuronal responsiveness. Biol Psychiatry 2008; 64: 626-35.
5. Arnsten AF. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 2006; 31: 2376-83.
6. Greenhill LL. Clinical effects of stimulant medication in ADHD. In Solanto MV, Arnsten AFT, Castellanos FX, editors. Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. New York: Oxford University Press, 31-71.
7. Wilens TE, Faraone SV, Biederman J. Attention-deficit/hyperactivity disorder in adults. JAMA 2004; 292: 619-23.
8. Simpson D, Plosker GL. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder. CNS Drugs 2004; 18: 397-401.
9. Hazell P. Pharmacological management of attention-deficit hyperactivity disorder in adolescents: special considerations. CNS Drugs 2007; 21: 37-46.
10. Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009; 23 Suppl 1: 21-31.
11. Froehlich TE, McGough JJ, Stein MA. Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs 2010; 24: 99-117.
12. Tsai MH, Huang YS. Attention-deficit/hyperactivity disorder and sleep disorders in children. Med Clin North Am 2010; 94: 615-32.
13. Weiss MD, Salpekar J. Sleep problems in the child with attentiondeficit hyperactivity disorder: defining aetiology and appropriate treatments. CNS Drugs 2010; 24: 811-28.
14. Konofal E, Lecendreux M, Cortese S. Sleep and ADHD. Sleep Med 2010; 11: 652-8.
15. Sung V, Hiscock H, Sciberras E, Efron D. Sleep problems in children with attention-deficit/hyperactivity disorder: prevalence and the effect on the child and family. Arch Pediatr Adolesc Med 2008; 162: 336-42.
16. Bullock GL, Schall U. Dyssomnia in children diagnosed with attention deficit hyperactivity disorder: a critical review. Aust N Z J Psychiatry 2005; 39: 373-7.
17. Cohen-Zion M, Ancoli-Israel S. Sleep in children with attentiondeficit hyperactivity disorder (ADHD): a review of naturalistic and stimulant intervention studies. Sleep Med Rev 2004; 8: 379-402.
18. Owens JA. The ADHD and sleep conundrum: a review. J Dev Behav Pediatr 2005; 26: 312-22.
19. Owens JA. Sleep disorders and attention-deficit/hyperactivity disorder Curr Psychiatry Rev 2008; 10: 439-44.
20. van der Heijden KB, Smits MG, Gunning WB. Sleep-related disorders in ADHD: a review. Clin Pediatr 2005; 44: 201-10.
21. Cortese S, Konofal E, Yateman N, Mouren MC, Lecendreux M. Sleep and alertness in children with attention-deficit/hyperactivity disorder: a systemic review of the literature. Sleep 2006; 29: 504-11.
22. Owens JA, Maxim R, Nobile C, McGuinn M, Msall M. Parental and self-report of sleep in children with attentiondeficit/ hyperactivity disorder. Arch Pediatr Adolesc Med 2000; 154: 549-55.
23. Silvestri R, Gagliano A, Aricò I, et al. Sleep disorders in children with attention-deficit/hyperactivity disorder (ADHD) recorded overnight by video-polysomnography. Sleep Med 2009; 10: 1132-8.
24. Konofal E, Lecendreux M, Bouvard MP, Mouren-Simeoni MC. High levels of nocturnal activity in children with attentiondeficit/ hyperactivity disorder: a video analysis. Psychiatry Clin Neurosci 2001; 55: 97-103.
25. Kent JD, Blader JC, Koplewicz HS, Abikoff H, Foley CA. Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. Pediatrics 1995; 96: 320-5.
26. Corkum P, Panton R, Ironside S, Macpherson M, Williams T. Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attentiondeficit/ hyperactivity disorder. J Pediatr Psychol 2008; 33: 368-79.
27. Day HD, Abmayr SD. Parent reports of sleep disturbances in stimulant-medicated children with attention-deficit hyperactivity disorder. J Clin Psychol 1998; 54: 701-16.
28. Kooij JJ, Middelkoop HA, van Gils K, Buitelaar JK. The effect of stimulants on nocturnal motor activity and sleep quality in adults with ADHD: an open-label case-control study. J Clin Psychiatry 2001; 62: 952-6.
29. Biederman J, Seidman LJ, Petty CR, et al. Effects of stimulant medication on neuropsychological functioning in young adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008; 69: 1150-6.
30. Brams M, Muniz R, Childress A, et al. A randomized, doubleblind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect. CNS Drugs 2008; 22 (8): 693-704.
31. Huang YS, Tsai MH. Long-term outcomes with medications for ADHD: current status of knowledge. CNS Drugs 2011 Jan [Epub ahead of print]
32. MTA Cooperative Group. National institute of mental health multimodal treatment study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004; 113: 762-9.
33. Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2005; 44: 1015-23.
34. Scheffler RM, Brown TT, Fulton BD, Hinshaw SP, Levine P, Stone S. Positive association between attentiondeficit/ hyperactivity disorder medication use and academic achievement during elementary school. Pediatrics 2009; 123: 1273-9.
35. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Faraone SV. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics 2009; 124: 71-8.
36. Yang P, Hsu HY, Chiou SS, Chao MC. Health-related quality of life in methylphenidate-treated children with attention-deficithyperactivity disorder: results from a Taiwanese sample. Aust N Z J Psychiatry 2007; 41: 998-1004.
37. Manos M, Frazier TW, Landgraf JM, Weiss M, Hodgkins P. HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. Curr Med Res Opin 2009; 25: 3001-10.
38. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficiency in attention deficit/ hyperactivity disorder. Neuro-psychopharmacology 2002; 27: 699-711.
39. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attentiondeficit/ hyperactivity disorder: a randomized, placebo-controlled, dose-respones study. Pediatrics 2001; 108: E83-91.
40. Dopheide JA. ASHP therapeutic position statement on the appropriate use of medications in the treatment of attentiondeficit/ hyperactivity disorder in pediatric patients. Am J Health Syst Pharm 2005; 62: 1502-9.
41. Garnock-Jones KP, Keating GM. Spotlight on atomoxetine in attention- deficit hyperactivity disorder in children and adolescents. CNS Drugs 2010; 24: 85-8.
42. Dell'Agnello G, Zuddas A, Masi G, Curatolo P, Besana D, Rossi A. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. CNS Drugs 2009; 23: 739-53.
43. Pliszka S, Crismon ML, Hughes CW, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45: 642-57.
44. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med. 2006; 8: 4.
45. Kelsey DK, Sumner CR, Casat CD, et al. Once-Daily Atomoxetine Treatment for Children With Attention-Deficit/Hyperactivity Disorder, Including an Assessment of Evening and Morning Behavior: A Double-Blind, Placebo-Controlled Trial. Pediatrics 2004; 114: e1-8.
46. Biederman J, Melmed RD, Patel A, et al. A randomized, doubleblind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008; 121: e73-84.
47. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit/hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2010; 24: 755-68.
48. May DE, Kratochvil CJ. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Drugs 2010; 70: 15-40.
49. Pliszka S, Crismon ML, Hughes CW, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45: 642-57.
50. Reimherr FW, Hedges DW, Strong RE, Marchant BK, Williams ED. Bupropion SR in adults with ADHD: a short-term, placebocontrolled trial. Neuropsychiatr Dis Treat 2005; 1: 245-51.
51. Brown RT, Amler RW, Freeman WS, et al. Treatment of attentiondeficit/ hyperactivity disorder: overview of the evidence. Pediatrics 2005; 115: e749-57.
52. Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attentiondeficit/ hyperactivity disorder among adolescents: a review of the diagnosis, treatment and clinical implications. Pediatrics 2005; 115: 1734-46.
53. Scahill L. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs 2009; 23: 43-9.
54. Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology 2009; 57: 608-18.
55. Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2008; 28: S46-53.
56. Heal DJ, Pierce DM. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 2006; 20: 713-38.
57. Boutrel B, Koob GF. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promising medications. Sleep 2004; 27: 1181-94.
58. Bricard C, Boidein F. Prescribing retalin in combined modality management of hyperactivity with attention deficit. Encephale 2001; 27: 435-43.
59. Burgess CR, Tse G, Gillis L, Peever JH. Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep 2010; 33: 1295-304.
60. Gruner JA, Marcy VR, Lin YG, Bozyczko-Coyne D, Marino MJ, Gasior M. The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents. Sleep 2009; 32: 1425-38.
61. Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 2008; 22: 213-37.
62. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/ hyperactivity disorder. Neuropsychopharmacology 2002; 27: 699-711.
63. Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP. Effects of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 2006; 50: 755-60.
64. Easton N, Steward C, Marshall F, Fone K, Marsden C. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology 2007; 52: 405-14.
65. Horner WE, Johnson DE, Schmidt AW, Rollema H. Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex. Eur J Pharmacol 2007; 558: 96-97.
66. Liu LL, Yang J, Lei GF, Wang GJ, Wang YW, Sun RP. Atomoxetine increases histamine release and improves learning deficits in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat. Basic Clin Pharmacol Toxicol 2008; 102: 527-32.
67. Stahl SM. Norepinephrine and dopamine regulate signals and noise in the prefrontal cortex. J Clin Psychiatry 2009; 70: 617-18.
68. Arnsten AFT. Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex 2007; 17: i6-i15.
69. Stahl SM. The prefrontal cortex is out of tune in attentiondeficit/ hyperactivity disorder. J Clin Psychiatry 2009; 70: 950-51.
70. Ramos BP, Arnsten AFT. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther 2007; 113: 523-36.
71. Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attentiondeficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2009; 19: 501-10.
72. Muir VJ, Perry CM. Guanfacine extended-release: in attention deficit hyperactivity disorder. Drugs 2010; 70: 1693-702.
73. Philbin KE, Bateman RJ, Mendelowitz D. Clonidine, an alpha2- receptor agonist, diminishes GABAergic neurotransmission to cardiac vagal neurons in the nucleus ambiguous. Brain Res 2010; 1347: 65-70.
74. Gentili A, Godschalk MF, Gheorghiu D, Nelson K, Julius DA, Mulligan T. Effect of clonidine and yohimbine on sleep in healthy men: a double-blind, randomized, controlled trial. Eur J Clin Pharmacol 1996; 50: 463-5.
75. Stahl SM. Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms. J Clin Psychiatry 2010; 71: 223-4.
76. Arnsten AF, Scahill L, Findling RL. Alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol 2007; 17: 393-406.
77. Dhillon S, Yang LP, Curran MP. Spotlight on bupropion in major depressive disorder. CNS Drugs 2008; 22: 613-7.
78. Zhao Z, Zhang HT, Bootzin E, Millan MJ, O'Donnell JM. Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs. Neuropsychopharmacology 2009; 34: 1467-81.
79. Verbeeck W, Tuinier S, Bekkering GE. Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systemic review. Adv Ther 2009; 26: 170-84.
80. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005; 20: 533-59.
81. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005; 65: 927-47.
82. Pandi-Perumal SR, Trakht I, Srinivasan V, et al. The effect of melatonergic and non-melatonergic antidepressants on sleep: weighting the alternatives. World J Biol Psychiatry 2009; 10: 342-54.
83. Meltzer LJ, Johnson C, Crosette J, Ramos M, Mindell JA. Prevalence of diagnosed sleep disorders in pediatric general care practices. Pediatrics 2010; 125: e1410-8.
84. O'Brien LM, Holbrook CR, Mervis CB, et al. Sleep and neurobehavioral characteristics of 5- to 7-year-old children with parentally reported symptoms of attention-deficit/hyperactivity disorder. Pediatrics 2003; 111: 554-63.
85. Owens J, Sangal RB, Sutton VK, Bakken R, Allen AJ, Kelsey D. Subjective and objective measures of sleep in children with attention- deficit/hyperactivity disorder. Sleep Med 2009; 10: 446-56.
86. Chervin RD, Archbold KH, Dillon JE, et al. Inattention, hyperactivity, and symptoms of sleep-disordered breathing. Pediatrics 2002; 109: 449-56.
87. Chervin RD, Archbold KH, Dillon JE, et al. Associations between symptoms of inattention, hyperactivity, restless, and periodic leg movements. Sleep 2002; 25: 213-8.
88. Cortese S, Konofal E, Lecendreux M, et al. Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature. Sleep 2005; 28: 1007-13.
89. Cortese S, Faraone SV, Konofal E, Lecendreux M. Sleep in children with attention-deficit/hyperactivity disorder: meta-analysis of subjective and objective studies. J Am Acad Child Adolesc Psychiatry 2009; 48: 894-908.
90. Sadeh A, Pergamin L, Bar-Haim Y. Sleep in children with attention- deficit hyperactivity disorder: a meta-analysis of polysomnographic studies. Sleep Med Rev 2006; 10: 381-98.
91. Stein D, Pat-Horenczyk R, Blank S, Dagan Y, Barak Y, Gumpel TP. Sleep disturbances in adolescents with symptoms of attentiondeficit/ hyperactivity disorder. J Learn Disabil 2002; 35: 268-75.
92. Greenhill L, Puig-Antich J, Goetz R, Hanlon C, Davies M. Sleep architecture and REM sleep measures in prepubertal children with attention deficit disorder with hyperactivity. Sleep 1983; 6: 91-101.
93. Ring A, Stein D, Barak Y, et al. Sleep disturbance in children with attention-deficit/hyperactivity disorder: a comparative study with healthy siblings. J Learn Disabil 1998; 31: 572-8.
94. Cohen-Zion M, Ancoli-Israel S. Sleep in children with attentiondeficit hyperactivity disorder (ADHD): a review of naturalistic and stimulant intervention studies. Sleep Med Rev 2004; 8: 379-402.
95. Stein MA. Unravelling sleep problems in treated and untreated children with ADHD. J Child Adolesc Psychopharmacol 1999; 9: 157-68.
96. Ahmann PA, Waltonen SJ, Olson KA, Theye FW, Van Erem AJ, Laplant RJ. Placebo-controlled evaluation of Ritalin side effects. Pediatrics 1993; 91: 1101-6.
97. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 1997; 100: 662-6.
98. Stein MA, Blondis TA, Schnitzer ER, et al. Methylphenidate dosing: twice daily versus three times daily. Pediatrics 1996; 98: 748-56.
99. O'Brien LM, Ivanenko A, Crabtree VM, et al. The effect of stimulants on sleep characteristics in children with attention deficit/ hyperactivity disorder. Sleep Med 2003; 4: 309-16.
100. Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Kelsey D. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep 2006; 29: 1573-85.
101. Boonstra AM, Kooij JJ, Oosterlaan J, Sergeant JA, Buitelaar JK, Van Someren EJ. Hyperactive night and day? Actigraphy studies in adult ADHD: a baseline comparison and the effect of methylphenidate. Sleep 2007; 30: 433-42.
102. Sobanski E, Schredl M, Kettler N, Alm B. Sleep in adults with attention deficit hyperactivity disorder (ADHD) before and during treatment with methylphenidate: a controlled polysomnographic study. Sleep 2008; 31: 375-81.
103. Galland BC, Tripp EG, Taylor BJ. The sleep of children with attention deficit hyperactivity disorder on and off methylphenidate: a matched case-control study. J Sleep Res 2010; 19: 366-73.
104. Ironside S, Davidson F, Corkum P. Circadian motor activity affected by stimulant medication in children with attentiondeficit/ hyperactivity disorder. J Sleep Res 2010; 19: 546-51.
105. Ramos-Quiroga JA, Bosch R, Castells X, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention- deficit hyperactivity disorder. CNS Drugs 2008; 22: 603-11.
106. Faraone SV, Glatt SJ, Bukstein OG, Lopez FA, Arnold LE, Findling FL. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J Atten Disord 2009; 12: 308-15.
107. Kim HW, Yoon IY, Cho SC, et al. The effect of OROS methylphenidate on the sleep of children with attention-deficit/hyperactivity disorder. Int Clin Psychopharmacol 2010; 25: 107-15.
108. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107: E105.
109. Pelham WE, Gnagy EM, Chronis AM, et al. A comparison of morning-only and morning/late afternoon Adderall to morningonly, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 1999; 104: 1300-11.
110. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attentiondeficit/ hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108: e83.
111. Greenhill LL, Newcorn JH, Gao H, Feldman PD. Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine. J Am Acad Child Adolesc Psychiatry 2007; 46: 566-72.
112. Prince JB, Wilens TE, Biederman J, Spencer TJ, Wozniak JR. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Psychiatry 1996; 35: 599-605.
113. Miyazaki S, Uchida S, Mukai J, Nishihara K. Clonidine effects on all-night human sleep: opposite action of low- and medium-dose clonidine on human NREM-REM sleep proportion. Psychiatry Clin Neurosci 2004; 58: 138-44.
114. Huynh N, Lavigne GJ, Lanfranchi PA, Montplaisir JY, de Champlain J. The effect of 2 sympatholytic medicationspropranolol and clonidine-on sleep bruxism: experimental randomized controlled studies. Sleep 2006; 29: 307-16.
115. Lavigne GJ, Rompre PH, Poirier G, Huard H, Kato T, Montplaisir JY. Rhythmic masticatory muscle activity during sleep in humans. J Dent Res 2001; 80: 443-8.
116. Carra MC, Macaluso GM, Rompré PH, et al. Clonidine has a paradoxical effect on cyclic arousal and sleep bruxism during NREM sleep. Sleep 2010; 33: 1711-6.
117. Faraone SV, Glatt SJ. Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD. J Atten Disord 2010; 13: 532-8.
118. Sallee FR, Lyne A, Wigal T, McGough JJ. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009; 19: 215-26.
119. Biederman J, Melmed RD, Patel A, McBurnett K, Donahue J, Lyne A. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr 2008; 13: 1047-55.